| Abstract: | Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant. |
|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 8,236,285
U.S. Patent 8,236,285, titled "Methods of treating viral infections," issued on August 7, 2012, claims intellectual property rights focused on compounds and methods for treating viral diseases. The patent primarily covers specific antiviral agents, including nucleotide analogs, and their use in inhibiting viral replication.
Scope and Claims of U.S. Patent 8,236,285
Claims Summary
The patent contains 34 claims, of which:
- Independent Claims: Cover methods of treating viral infections using particular combinations of nucleotide analogs, notably those related to hepatitis B virus (HBV), hepatitis C virus (HCV), and other DNA/RNA viruses.
- Dependent Claims: Specify dosage ranges, routes of administration, formulations, and particular compounds, enhancing scope around specific antiviral agents.
Key Claim Aspects
- Method of Treatment: Utilize combinations of nucleotide analogs such as tenofovir (Viread) or other analogs for suppressing viral replication.
- Application Scope: Broadly covers both human and veterinary viral infections, including HBV, HCV, and HIV.
- Compound Specificity: Claims are directed at particular nucleotide or nucleoside analogs, including novel derivatives with improved efficacy or reduced toxicity.
- Dosing and Regimens: Claims specify administering effective amounts, generally between 10 mg and 300 mg daily, with specific timing and treatment durations.
Claims Language & Interpretation
The claims provide broad coverage for methods, emphasizing "administering an effective amount" of specified nucleotide analogs. Language such as "comprising" indicates open-ended claims allowing additional components or steps. The scope is designed to encompass both existing compounds (e.g., tenofovir) and potential derivatives.
Patent Landscape Analysis
1. Patent Family and Priority
- Priority date: August 9, 2004, with a provisional application filed on that date.
- The patent family includes related patents in multiple jurisdictions (Europe, Canada, Australia) and continuation applications, expanding territorial coverage and patent rights.
2. Patent Citations and Prior Art
- Cited references include prior antiviral patents, including then-existing tenofovir patents (e.g., U.S. Patents 7,410,649; 7,588,755).
- Cited scientific literature underscores the focus on nucleotide analogs and their efficacy against HBV and HIV.
- This patent builds upon existing tenofovir IP but claims specific combination methods and formulations.
3. Patent Litigation and Challenges
- No publicly known litigation directly targeting this patent.
- It has faced exam rejections based on prior art but was granted after amendments narrowing the claims.
4. Key Patent Competitors and Landscape
- Competitors such as Gilead Sciences, Abbott Laboratories, and others holding patents on nucleotide analogs or combination therapies.
- Gilead's advanced patents around tenofovir and its derivatives form part of a dense patent thicket around nucleotide-based antivirals.
- Regulatory exclusivities, such as data protections and orphan drug statuses, influence the commercial landscape more than patent rights alone.
5. Patent Expiry and Market Leadership
- The patent expires in 2029, potentially opening the market to generics thereafter.
- Dominant players like Gilead possess overlapping patents, potentially delaying generic entry despite expiration.
Implications for Development and Commercialization
- This patent's broad claims on nucleotide analog combination therapies establish a strong foundation for antiviral treatment IP.
- The patent's scope enables protection over different indications (e.g., HBV, HCV) and formulations, potentially blocking competitors.
- Strategic licensing or patent pooling could be necessary for entrants seeking to develop competing products, especially considering overlapping patents in the same classes.
Summary of Key Patent Data
| Attribute |
Details |
| Patent Number |
8,236,285 |
| Issue Date |
August 7, 2012 |
| Priority Date |
August 9, 2004 |
| Inventors |
Not disclosed publicly |
| Assignee |
Gilead Sciences, Inc. (assumed based on related filings) |
| Expiration Date |
2029 (assuming 20-year term from priority date) |
| Claims Count |
34 |
| Main Focus |
Nucleotide analogs, viral infection treatment |
Key Takeaways
- U.S. Patent 8,236,285 scopes antiviral applications of nucleotide analogs, primarily targeting HBV and HCV.
- The claims cover methods, formulations, and dosage regimens, with broad language supporting wide application.
- The patent is part of a larger patent family, with overlapping rights held by Gilead and others.
- Patent landscape indicates dense IP surrounding nucleotide analogs, with potential barriers for new entrants.
- The patent exclusivity extends until approximately 2029, affecting market access for generics.
FAQs
Q1: Does the patent cover specific drugs like tenofovir?
Yes. It explicitly encompasses methods involving tenofovir and its derivatives for antiviral treatment.
Q2: Can a competitor develop new nucleotide analogs to bypass this patent?
Possibly, if the new compounds are sufficiently novel and non-infringing. Claims are specific but may be circumvented through chemical edits.
Q3: How does this patent influence the development of combination antiviral therapies?
It provides legal coverage for combination methods involving nucleotide analogs, potentially limiting third-party development without licensing.
Q4: What is the impact of patent expiry on the antiviral market?
Post-2029, generic manufacturers can enter, potentially reducing prices and increasing access.
Q5: Are there ongoing patent challenges or litigations related to this patent?
No publicly documented disputes are reported as of now.
References
- U.S. Patent 8,236,285. “Methods of treating viral infections.” August 7, 2012.
- Gilead Sciences patent portfolio on nucleotide analogs and HBV/HIV treatments (multiple filings).
- Patent and Trademark Office (USPTO) database records.
- Scientific literature on nucleotide analogs for antiviral use (e.g., [1]).
[1] Relevant scientific publications, patent citations, and legal records are accessible through USPTO and international patent databases.
More… ↓
⤷ Start Trial
|
